Jan. 08 LunchTime Movers Board: Ambrx Biopharma rockets 98% after reaching an acquisition agreement with JNJ

Seize the market opportunities with us at 8:45 every morning, and don't forget to check our "Lunchtime Movers Board" at 12:00.

LunchTime Gainers: Ambrx, Aclarion, Axonics, Cellectar, Vivos

AMAM:

Ambrx Biopharma rockets 98% after reaching an acquisition agreement with JNJ.

ACON:

Aclarion soars 81% after announcing partnership agreement with Alphatec Spine.

AXNX:

Axonics, Inc jumps 20% after Boston Scientific announced agreement to acquire the Co.

CLRB:

Cellectar BioSciences surges 15% after announcing Positive topline data achieving primary endpoint in pivotal clinical study of Iopofosine I 131 in Waldenstrom"s macroglobulinemia.

VVOS:

Vivos Therapeutics climbs 5% after seeing positive preliminary metrics following unprecedented FDA 510(k) clearance of the company"s proprietary oral medical devices to treat severe OSA.

LunchTime Losers: Solo, Dada, Prothena, Evolve, Zim

DTC:

Solo Brands stock plunges 32% after guidance cut.

DADA:

Dada Nexus slumps 30% as the Co. found questionable conduct during routing internal audits.

PRTA:

Prothena slumps 26% after providing upset updates on PRX012, PRX123, Birtamimab and portfolio programs.

SNMP:

Evolve Transition Infrastructure slides 17% after reporting exercise of right to purchase common units.

ZIM:

Zim Integrated Shipping sinks 10% after China"s COSCO halted shipping to Israel.

$AMAM(AMAM)$ACON(ACON)$AXNX(AXNX)$CLRB(CLRB)$VVOS(VVOS)$DTC(DTC)$PRTA(PRTA)$SNMP(SNMP)$ZIM(ZIM)$DADA(DADA)